{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:03:33Z","timestamp":1740107013338,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00520-021-06340-4","type":"journal-article","created":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T03:50:26Z","timestamp":1628567426000},"page":"981-984","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Risk factors of skeletal-related events in patients with bone metastatic castration-resistant prostate cancer undergoing treatment with zoledronate"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0433-9779","authenticated-orcid":false,"given":"Hirotaka","family":"Miyashita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaibhav","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,10]]},"reference":[{"key":"6340_CR1","doi-asserted-by":"publisher","unstructured":"D\u2019Oronzo S, Coleman R, Brown J, Silvestris F. Metastatic bone disease: Pathogenesis and therapeutic options: up-date on bone metastasis management. J Bone Oncol. 2019;15. https:\/\/doi.org\/10.1016\/j.jbo.2018.10.004","DOI":"10.1016\/j.jbo.2018.10.004"},{"issue":"9","key":"6340_CR2","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1007\/s00520-019-4635-5","volume":"27","author":"A Bongiovanni","year":"2019","unstructured":"Bongiovanni A, Recine F, Fausti V et al (2019) Ten-year experience of the multidisciplinary Osteoncology Center. Support Care Cancer 27(9):3395\u20133402. https:\/\/doi.org\/10.1007\/s00520-019-4635-5","journal-title":"Support Care Cancer"},{"key":"6340_CR3","doi-asserted-by":"publisher","unstructured":"Miyashita H, Cruz C, Smith C. Risk factors of skeletal-related events in patients with bone metastasis from non-small cell lung cancer undergoing treatment with zoledronate\u2014a post hoc analysis of a randomized clinical trial. Support Care Cancer. 2020:1\u20135. https:\/\/doi.org\/10.1007\/s00520-020-05665-w","DOI":"10.1007\/s00520-020-05665-w"},{"issue":"1","key":"6340_CR4","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00520-014-2437-3","volume":"23","author":"MS Broder","year":"2015","unstructured":"Broder MS, Gutierrez B, Cherepanov D, Linhares Y (2015) Burden of skeletal-related events in prostate cancer: unmet need in pain improvement. Support Care Cancer 23(1):237\u2013247. https:\/\/doi.org\/10.1007\/s00520-014-2437-3","journal-title":"Support Care Cancer"},{"issue":"2","key":"6340_CR5","doi-asserted-by":"publisher","first-page":"106","DOI":"10.12809\/hkmj144449","volume":"22","author":"KW Wong","year":"2016","unstructured":"Wong KW, Ma WK, Wong CW et al (2016) Impact of skeletal-related events on survival in patients with metastatic prostate cancer prescribed androgen deprivation therapy. Hong Kong Med J 22(2):106\u2013115. https:\/\/doi.org\/10.12809\/hkmj144449","journal-title":"Hong Kong Med J"},{"issue":"15","key":"6340_CR6","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1200\/JCO.19.03148","volume":"38","author":"PJ Saylor","year":"2020","unstructured":"Saylor PJ, Rumble RB, Tagawa S et al (2020) Bone health and bone-targeted therapies for prostate cancer: ASCO endorsement of a cancer care ontario guideline. J Clin Oncol 38(15):1736\u20131743. https:\/\/doi.org\/10.1200\/JCO.19.03148","journal-title":"J Clin Oncol"},{"issue":"9768","key":"6340_CR7","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377(9768):813\u2013822. https:\/\/doi.org\/10.1016\/S0140-6736(10)62344-6","journal-title":"Lancet"},{"issue":"9","key":"6340_CR8","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1002\/cncr.30505","volume":"123","author":"Z Klaassen","year":"2017","unstructured":"Klaassen Z, Howard LE, de Hoedt A et al (2017) Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer. Cancer 123(9):1528\u20131535. https:\/\/doi.org\/10.1002\/cncr.30505","journal-title":"Cancer"},{"issue":"6","key":"6340_CR9","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/sj.bjc.6602767","volume":"93","author":"A Berruti","year":"2005","unstructured":"Berruti A, Tucci M, Mosca A et al (2005) Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease. Br J Cancer 93(6):633\u2013638. https:\/\/doi.org\/10.1038\/sj.bjc.6602767","journal-title":"Br J Cancer"},{"key":"6340_CR10","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.12659\/msm.900977","volume":"23","author":"Y Chen","year":"2017","unstructured":"Chen Y, Lin Y, Nie P et al (2017) Associations of prostate-specific antigen, prostate carcinoma tissue gleason score, and androgen receptor expression with bone metastasis in patients with prostate carcinoma. Med Sci Monit 23:1768\u20131774. https:\/\/doi.org\/10.12659\/msm.900977","journal-title":"Med Sci Monit"},{"issue":"24","key":"6340_CR11","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1001\/jama.2017.7248","volume":"317","author":"MS Litwin","year":"2017","unstructured":"Litwin MS, Tan HJ (2017) The diagnosis and treatment of prostate cancer: a review. JAMA J Am Med Assoc 317(24):2532\u20132542. https:\/\/doi.org\/10.1001\/jama.2017.7248","journal-title":"JAMA J Am Med Assoc"},{"issue":"3","key":"6340_CR12","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s10549-010-0981-1","volume":"123","author":"JE Brown","year":"2010","unstructured":"Brown JE, Cook RJ, Lipton A, Costa L, Coleman RE (2010) Prognostic factors for skeletal complications from metastatic bone disease in breast cancer. Breast Cancer Res Treat 123(3):767\u2013779. https:\/\/doi.org\/10.1007\/s10549-010-0981-1","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"6340_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster JY (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30(1):3\u201344. https:\/\/doi.org\/10.1007\/s00198-018-4704-5","journal-title":"Osteoporos Int"},{"issue":"2","key":"6340_CR14","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/1097-0142(20000715)89:2<363::AID-CNCR22>3.0.CO;2-3","volume":"89","author":"SM Domchek","year":"2000","unstructured":"Domchek SM, Younger J, Finkelstein DM, Seiden MV (2000) Predictors of skeletal complications patients with breast carcinoma. Cancer 89(2):363\u2013368. https:\/\/doi.org\/10.1002\/1097-0142(20000715)89:2%3c363::AID-CNCR22%3e3.0.CO;2-3","journal-title":"Cancer"},{"issue":"2","key":"6340_CR15","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/JTO.0000000000000051","volume":"9","author":"N Katakami","year":"2014","unstructured":"Katakami N, Kunikane H, Takeda K et al (2014) Prospective study on the incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage IIIB and IV lung cancer - CSP-HOR 13. J Thorac Oncol 9(2):231\u2013238. https:\/\/doi.org\/10.1097\/JTO.0000000000000051","journal-title":"J Thorac Oncol"},{"issue":"3","key":"6340_CR16","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/j.1464-410X.2011.10192.x","volume":"109","author":"K Izumi","year":"2012","unstructured":"Izumi K, Mizokami A, Itai S et al (2012) Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal-related events in patients with prostate cancer with bone metastasis. BJU Int 109(3):394\u2013400. https:\/\/doi.org\/10.1111\/j.1464-410X.2011.10192.x","journal-title":"BJU Int"},{"issue":"2","key":"6340_CR17","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1080\/13102818.2007.10817444","volume":"21","author":"F Sara\u00e7","year":"2007","unstructured":"Sara\u00e7 F, Sayg\u0131l\u0131 F (2007) Causes of high bone alkaline phosphatase. Biotechnol Biotechnol Equip 21(2):194\u2013197. https:\/\/doi.org\/10.1080\/13102818.2007.10817444","journal-title":"Biotechnol Biotechnol Equip"},{"issue":"6","key":"6340_CR18","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1111\/bcp.13866","volume":"85","author":"L Bedatsova","year":"2019","unstructured":"Bedatsova L, Drake MT (2019) The skeletal impact of cancer therapies. Br J Clin Pharmacol 85(6):1161\u20131168. https:\/\/doi.org\/10.1111\/bcp.13866","journal-title":"Br J Clin Pharmacol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06340-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-021-06340-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06340-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T09:06:14Z","timestamp":1641287174000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-021-06340-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,10]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["6340"],"URL":"https:\/\/doi.org\/10.1007\/s00520-021-06340-4","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2021,8,10]]},"assertion":[{"value":"16 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consented for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}